During an interview with CNBC, Eli Lilly CEO Dave Ricks highlighted that one-third of new patients prescribed GLP-1 medications are using Foundayo, indicating a growing market share for Lilly in this competitive space.
The company is actively working to expand its presence internationally and has recently broken ground on a $6.5 billion manufacturing facility in Houston, Texas, which is expected to be operational by 2030. This facility will primarily produce Foundayo and other small-molecule medicines across various therapeutic areas.
Ricks expressed confidence in Lilly's long-term prospects in the oral medication segment, especially as the company reported a 61% share of the overall market in the second quarter.
The demand for Foundayo is expected to increase further due to Medicare's recent coverage of obesity drugs, which began in July, potentially enhancing access to both Foundayo and Lilly's other weight loss drug, Zepbound.
Lilly's commitment to reshoring manufacturing and investing over $50 billion since 2020 positions it well to meet the rising demand for obesity and diabetes treatments, especially as it seeks to outpace its main competitor, Novo Nordisk, which has faced investor concerns regarding its long-term strategy in this market